These Form 3 filings are administrative and carry no trading signal. Monitor for future Form 4 filings to track any insider transactions that may provide directional insight.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $34.00entry
- T+1 · 7mo ago −25.47%α −25.13% · $25.34
- T+5 · 6mo ago −26.12%α −28.46% · $25.12
- T+20 · 6mo ago −20.21%α −25.47% · $27.13
- T+60 · 4mo ago +39.00%α +35.93% · $47.26
Price Chart
How similar events traded
Executive Summary
Two insiders at Hemab Therapeutics (COAG) filed initial statements of beneficial ownership (Form 3) on April 30, 2026, disclosing warrant holdings. Director Akshay Vaishnaw holds warrants to buy 65,340 shares at exercise prices of $6.97 and $6.00, while Chief Medical Officer Catherine Madigan holds warrants to buy 310,376 shares at $7.67 and $6.00. These are routine initial ownership filings triggered by the insiders' positions and do not reflect any new transactions or material corporate events.
Key Facts
- Director Akshay Vaishnaw filed Form 3 disclosing warrants for 65,340 shares of common stock.
- Chief Medical Officer Catherine Madigan filed Form 3 disclosing warrants for 310,376 shares of common stock.
- Vaishnaw's warrants have exercise prices of $6.97 (expiring May 7, 2034) and $6.00 (expiring January 28, 2036).
- Madigan's warrants have exercise prices of $7.67 (expiring February 9, 2035) and $6.00 (expiring January 28, 2036).
- Both filings include standard powers of attorney authorizing company officers to file SEC reports on their behalf.
Financial Impact
No financial impact, routine insider ownership disclosure with no new transactions or material changes.
Risk Factors
- No material risks identified from these routine filings.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (COAG), Batch item 1 | 0001193125-26-198190 |
| Document: 0001193125-26-198190-index-headers.html | 0001193125-26-198189 |
| Document: 0001193125-26-198190-index.html | 0001193125-26-198190 |
| Document: 0001193125-26-198190.txt | 0001193125-26-198190 |
| 3 Filing (COAG), Batch item 5 | 0001193125-26-198189 |
| Document: 0001193125-26-198189-index-headers.html | 0001193125-26-198190 |
| Document: 0001193125-26-198189-index.html | 0001193125-26-198190 |
| Document: 0001193125-26-198189.txt | 0001193125-26-198190 |
Track record
19 reports on COAG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $38.77 Now $39.06 +0.75% settles Nov 17
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $42.81 to $39.06 Now $39.06 −8.76% ▼ −8.77% −7.08% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $49.02 to $40.86 Now $39.06 −20.32% ▼ −16.65% −19.24% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $45.09 to $39.33 Now $39.06 −13.37% ▼ −12.77% −11.86% vs SPY
- Sep 25, 20267w ago 3 Neutral 2/10 Entry $33.12 to $30.59 Now $39.06 +17.93% ▼ −7.64% −8.84% vs SPY
- Sep 17, 20268w ago Press Release Neutral 4/10 Entry $41.22 to $35.72 Now $39.06 −5.24% ▼ −13.34% −14.19% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 Entry $49.87 to $52.44 Now $39.06 −21.68% ▲ +5.15% +5.56% vs SPY
- Jun 17, 202621w ago Insider Buy Neutral 2/10 Entry $29.24 to $27.72 Now $39.06 +33.58% ▼ −5.20% −3.53% vs SPY
- May 21, 202625w ago Press Release Neutral 5/10 Entry $26.30 to $28.50 Now $39.06 +48.52% ▲ +8.37% +6.52% vs SPY
- May 4, 202628w ago 8-K Neutral 4/10 Entry $25.00 to $25.90 Now $39.06 +56.24% ▲ +3.60% +1.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers